Clinical trials
Adult clinical trials
Below are recruiting adult clinical trials, each written for real people, not researchers. We’re tracking 3,742 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04971850Recruiting
Sleep study for children with possible breathing sleep problems
This trial looks at sleep-related breathing problems (“sleep-disordered breathing”) in children and young adults and how they may affect thinking and memory using sleep study testing plus neurocognitive (thinking) assessments. It may help doctors better understand symptoms and identify who could benefit from treatment.
ParisAges 1–20 - NCT04972136Recruiting
Brain stimulation treatment for depression in young adults with autism
This trial studies a noninvasive brain stimulation (rTMS) to help reduce depression symptoms in young adults who have autism. It aims to find out if this treatment can improve mood and daily functioning without requiring recent changes to medications.
Toronto, OntarioAges 16–35 - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Gilbert, ArizonaAges 18 years+ - NCT04989491RecruitingPhase 4
Single-dose rituximab to prevent EBV after kidney transplant
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
StrasbourgAges 18 years+ - NCT04993885RecruitingPhase 2
Avatrombopag for adults with immune low platelets
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05003388RecruitingPhase 1
Safety study of IV stem cells from donor umbilical cord
This early study tests whether an IV infusion of donor-derived stem cells is safe for people with multiple sclerosis. It mainly focuses on side effects and safety, not whether it improves MS symptoms yet.
St John'sAges Any age - NCT05003960RecruitingPhase 1
Testing an IV stem cell treatment for autism safety
This trial tests whether an IV infusion of lab-made donor stem cells is safe for people with autism. It mainly looks at side effects and whether the treatment can be given without causing harm.
St John'sAges Any age - NCT05003947RecruitingPhase 1
Stem cell infusion for Crohn’s or ulcerative colitis safety
This Phase 1 trial tests whether an IV infusion of donated (allogeneic) stem cells is safe in people with Crohn’s disease or ulcerative colitis. It focuses mainly on safety and tolerability, and it may offer a new treatment approach if you qualify.
St John'sAges Any age - NCT05003934RecruitingPhase 1
IV stem cell treatment safety study for rheumatoid arthritis
This Phase 1 trial tests how safe an intravenous (through a vein) stem cell product is for people with rheumatoid arthritis. It is mainly looking for side effects and safety rather than proving it works yet.
St John'sAges Any age - NCT05004116RecruitingPhase 1/Phase 2
Repotrectinib plus chemotherapy for relapsed solid tumors in youth
This early-phase study tests repotrectinib (a targeted anti-cancer pill) combined with chemotherapy in children and young adults whose solid tumors have come back or did not respond to standard treatment. The goal is to see how safe the treatment is and whether it can shrink tumors.
New York, New YorkAges 1–25 - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05015439RecruitingPhase 1
CBD study for adults with autism and challenging symptoms
This Phase 1 study tests cannabidiol (CBD) in adults on the autism spectrum who also have mood, sleep, or behavior problems. The goal is to learn whether CBD can be given safely and may help symptoms that affect daily life.
Baltimore, MarylandAges 18 years+ - NCT05016817RecruitingPhase 1
Testing an IV stem cell treatment for idiopathic pulmonary fibrosis
This Phase 1 study tests whether an IV infusion of stem cells from donated umbilical cord tissue is safe for people with idiopathic pulmonary fibrosis. It focuses mainly on safety and tolerability, and it may help by offering a new treatment approach if the cells are safe for you.
St John'sAges Any age - NCT05016804RecruitingPhase 1
Umbilical cord stem cell infusion trial for systemic sclerosis
This early safety study tests whether an intravenous (through a vein) stem cell product made from donated umbilical cord cells is safe for people with systemic sclerosis. If you join, the goal is to see how your body tolerates the treatment and monitor for side effects.
St John'sAges Any age - NCT05018845RecruitingPhase 1
Testing a donated stem cell treatment for chronic kidney disease
This early study (Phase 1) tests whether an intravenously given, donated stem cell product is safe for people with chronic kidney disease. It mainly looks at side effects and whether the treatment can be given without harming you.
St John'sAges Any age - NCT05018819RecruitingPhase 1
IV stem cell treatment for cerebral palsy safety
This trial tests whether an IV infusion of lab-grown stem cells from donated umbilical cord is safe for people with cerebral palsy. It mainly focuses on side effects and safety rather than proving it works.
St John'sAges Any age - NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Boston, MassachusettsAges 12 years+ - NCT05022940Recruiting
Track recovery and participation after adult brain injury rehab
This study follows adults with traumatic brain injury (TBI) during and after rehabilitation, to better understand how recovery and daily participation change over time. It may help improve rehab programs for people like you in the future.
Montreal, QuebecAges 17 years+ - NCT05023785Recruiting
Lifestyle program for cancer survivors with early heart strain
This trial tests a structured lifestyle and exercise change program for young people who finished cancer treatment and have signs of early heart weakness. The goal is to improve heart health and lower the chance of heart failure later.
Toronto, OntarioAges 18–45 - NCT05025098RecruitingPhase 2
Targeted treatment versus standard care for older blood cancer patients
This Phase 2 trial compares a “precision” treatment plan with standard therapy for older adults with AML or MDS. It aims to improve outcomes while using treatments that may be better suited for people who cannot have intensive chemotherapy.
LørenskogAges 60 years+ - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05037760RecruitingPhase 2
Elritercept alone or with ruxolitinib for myelofibrosis
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
Concord, New South WalesAges 18 years+ - NCT05038696RecruitingPhase 1
CAR T-cell treatment for hard-to-control B-ALL
This Phase 1 trial tests a personalized “CAR T” cell treatment for people with relapsed or treatment-resistant B-lymphoblastic leukemia (B-ALL). It may help the immune system find and kill leukemia cells, especially when leukemia has not responded to standard treatment.
SingaporeAges 6 months–80 years - NCT05040178Recruiting
Study of Carbaglu® use for MMA and PA
This observational study looks at how Carbaglu® is used and how well it works for people with methylmalonic acidemia (MMA) or propionic acidemia (PA). It may help doctors understand real-world care for adults and children living with these conditions.
Washington D.C., District of ColumbiaAges Any age
Hear when a new Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adult?
- Yes. Clin2 currently lists 3,742 recruiting adult studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adult trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adult trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.